熱門資訊> 正文
Citius Oncology宣布注册直接发行1800万美元
2025-12-09 21:49
- Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced on Tuesday that it has entered into a definitive agreement with a single healthcare-focused investor for the purchase and sale of 1.28 million shares of its common stock at a purchase price of $1.09 per share in a registered direct offering.
- In addition, the company has agreed to issue to the investor unregistered warrants to purchase up to 1.28 million shares of common stock at an exercise price of $1.09 per share, which will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval.
- Concurrently with the registered direct offering, in a private placement priced at-the-market under Nasdaq rules, the company entered into a definitive agreement with the investor for the purchase and sale of 15.23 million shares of common stock and warrants to purchase up to 15.23 million shares of the company's common stock at a purchase price of $1.09 per share and accompanying warrant.
- The warrants to be issued in the private placement have an exercise price of $1.09 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval.
- The closing of the offerings is expected to occur on or about December 10, 2025.
- The gross proceeds from the offerings, before deducting the placement agent's fees and other offering expenses payable by the company, are expected to be approximately $18 million.
- The company intends to use the net proceeds from the offerings to support the commercial launch of LYMPHIR and for working capital and general corporate purposes.
- CTXR -7.14% premarket to $1.04.
- Source: Press Release
More on Citius Pharmaceuticals, Citius Oncology
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
- Financial information for Citius Pharmaceuticals
- Seeking Alpha’s Quant Rating on Citius Oncology
- Historical earnings data for Citius Oncology
推薦文章
華盛早報 | 黃金、白銀狂飆！特朗普「威脅」引地緣政治風險升溫；商業航天爆發！中國新增20萬顆衞星申請
港股周報 | 超配中國！高盛稱中國股市26年大漲15%至20%；阿里稱堅定加大淘寶閃購投入
2026年展望 | 智能駕駛元年或開啟！特斯拉Robotaxi引爆賽道，港美股哪些標的值得佈局？
美股機會日報 | 重磅大考！「非農+關税裁決」今夜同台亮相；Meta宣佈將投資核電廠，OKLO等核電股盤前飆升！
一周財經日曆 | 美國12月CPI攜手「恐怖數據」來襲；華爾街大行啟動Q4財報季，臺積電財報或炸場！4只港股新股即將上市
一周IPO | 吃大肉！本周六只新股上市大漲，MINIMAX暴漲109%；BBSB INTL孖展倍數超8900倍，位列史上第三
財報前瞻 | 臺積電Q4營收料衝破萬億新臺幣！大摩喊話績前買入，2026年股價還能「繼續飛」嗎？
MiniMax上市首日漲超60%，阿里、米哈遊等投資方「躺贏」
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
